79
Participants
Start Date
May 24, 2021
Primary Completion Date
January 20, 2022
Study Completion Date
January 20, 2022
NTP42:KVA4
Single ascending dose (SAD) or multiple ascending dose (MAD) of NTP42:KVA4 administered to healthy volunteers as an oral suspension.
Placebo
Placebo, matched to corresponding doses of NTP42:KVA4 administered to healthy volunteers as an oral solution.
Hammersmith Medicines Research, London
Lead Sponsor
Hammersmith Medicines Research
OTHER
ATXA Therapeutics Limited
INDUSTRY